560 Purushottam Das Soni, I.P Tripathi , M.K. Dwivedi International Journal of Engineering Technology Science and Research IJETSR www.ijetsr.com ISSN 2394 – 3386 Volume 4, Issue 8 August 2017 QSAR Study of Some Anti-Hepatitis B Virus Agents Comprising 4-Aryl-6-Chloro-Quinolin-2-Ones and 5-Aryl-7- Chloro-1,4- Benzodiazepines Purushottam Das Soni Faculty of Science &Environment, M.G.C.G. University, Chitrakoot, Satna (M.P.) I.P Tripathi Faculty of Science &Environment, M.G.C.G. University, Chitrakoot, Satna (M.P.) M.K. Dwivedi* Department of Chemistry, Govt. Holkar Science College, Indore (M.P.) ABSTRACT QSAR analysis on a set of synthesized 4-Aryl-6-chloro-quinolin-2-ones and 5-Aryl-7-Chloro-1, 4-benzodiazepines analogues tested fir growth inhibitory antiviral activity was performed by using MLR procedure. The activity contributions of these compounds were determined from regression equation and the validation procedures to analyze the predictive ability of QSAR models were described. The results are discussed on the basis of statistical data. High agreements between experimental and predicted antiviral activity inhibitory values are obtained. The results of this study indicate that the substitution of electron withdrawing group, aromatic ring , polarizability etc. parameters has significant effect on antiviral activity of this class of compounds thus simplifying design of new biological active molecule. KEY WORDS QSAR, MLR, Antiviral Activity INTRODUCTION Hepatitis B virus (HBV), a member of the hepadnavirus (hepatotropic DNA virus) family, has caused a global health crisis as the ninth leading cause of death in the world by chronically infecting more than 400 million people according to the World Health Organization (WHO).HBV is a fatal disease epidemic in Southeast Asia, Africa and China, where approximately 10% of the populations are chronic carriers. People infected with HBV are at risk of chronic hepatitis, liver failure, cirrhosis, and hepatocellular carcinoma leading to significant mortality and serious long-term morbidity, which are 10 times more numerous than HIV (human immunodeficiency virus) patients. No effective therapy against HBV infection has been fully developed so far and the molecular mechanisms of HBV-mediated hepatocarcinogenesis are still poorly understood. Therefore, continued progress for the effective therapy of chronic HBV infection is still an urgent demand worldwide. Treatment of chronic HBV infection is aimed at suppressing viral replication to the lowest possible level, and thereby to halt the progression of liver disease and prevent the onset of complications. The licensed vaccine against HBV is an effective mean to prevent infection. A successful example is the national hepatitis B vaccination program in Taiwan of China. But vaccine is not an effective therapeutic strategy to treat established chronic infections when used alone. Two categories of anti-viral drugs have been approved for the treatment of hepatitis B:1,9,12,15 interferon-α (IFN-α) and nucleoside analogues such as lamivudine (3TC), adefovir dipivoxil and entecavir (ETV). However, unresolved critical issues make the current treatment regimens far from satisfactoriness. Relatively low cure rate, dose- dependent side effects and quick accumulation of drug resistant mutants have limited their extensive application.